Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Benitec Biopharma's Cash from Financing Activities history spans 6 years, with the latest figure at $28.4 million for Q1 2025.

  • For Q1 2025, Cash from Financing Activities changed N/A year-over-year to $28.4 million; the TTM value through Mar 2025 reached $108.0 million, up 286.34%, while the annual FY2024 figure was $68.0 million, 324.78% up from the prior year.
  • Cash from Financing Activities for Q1 2025 was $28.4 million at Benitec Biopharma, up from $17.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $40.1 million in Q2 2024 and bottomed at $3000.0 in Q1 2021.
  • The 5-year median for Cash from Financing Activities is $17.9 million (2024), against an average of $18.3 million.
  • The largest YoY upside for Cash from Financing Activities was 45720.51% in 2024 against a maximum downside of 22.43% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $12.7 million in 2021, then rose by 26.42% to $16.0 million in 2022, then crashed by 99.76% to $39000.0 in 2023, then soared by 45720.51% to $17.9 million in 2024, then skyrocketed by 59.0% to $28.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Cash from Financing Activities are $28.4 million (Q1 2025), $17.9 million (Q4 2024), and $21.7 million (Q3 2024).